Michael Ku and Global Clinical Supply at Pfizer Inc.

:
Bringing Hope to Patients (C)

Ashish
PGP13044
DSC-07

Problem Statement:
Global Clinical Supply (GCS) at Pfizer Inc. is facing a number of challenges, including
increasing complexity of clinical trials, increasing globalization of clinical trials, and
increasing competition from other pharmaceutical companies.

Objectives:
 To improve the efficiency and effectiveness of GCS.
 To reduce the cost of clinical trials.
 To bring new drugs to market more quickly.
 To maintain a high level of quality and compliance.

Target Audience:
Pfizer management team

Decision:
GCS should implement the following strategy:
 Invest in digital technology: GCS should invest in digital technology to improve
the efficiency and effectiveness of its operations. This could include investing in
new software systems, data analytics tools, and artificial intelligence.
 Expand its global network: GCS should expand its global network to support
Pfizer's growing pipeline of global clinical trials. This could involve opening new
offices in key markets and partnering with local suppliers and service providers.
 Build a culture of innovation: GCS should build a culture of innovation to
encourage employees to develop new and better ways to do things. This could
involve creating a dedicated innovation team, providing funding for employee
innovation projects, and rewarding employees for innovative ideas.
Implementation Plan:
GCS should establish a cross-functional team to develop and implement the new strategy.
The team should include representatives from all departments, such as clinical operations,
supply chain management, and information technology.
The team should start by conducting a needs assessment to identify the specific areas where
digital technology can be used to improve the efficiency and effectiveness of GCS's
operations. The team should also develop a plan to expand GCS's global network and build a
culture of innovation.
Once the team has developed a new strategy, they should develop a plan to implement it. This
plan should include specific timelines and budgets for each initiative.
Potential Benefits and Risks:

The potential benefits of implementing the new strategy include:

 Increased efficiency and effectiveness of GCS's operations

 Reduced cost of clinical trials
 Ability to bring new drugs to market more quickly
 Improved quality and compliance

The potential risks of implementing the new strategy include:

 Cost of investing in digital technology

 Challenges of expanding GCS's global network
 Difficulty of building a culture of innovation

Conclusion:
GCS needs to implement a new strategy to improve its efficiency and effectiveness, reduce
the cost of clinical trials, bring new drugs to market more quickly, and maintain a high level
of quality and compliance. The new strategy should focus on investing in digital technology,
expanding GCS's global network, and building a culture of innovation. GCS should establish
a cross-functional team to develop and implement the new strategy.

Recommendation:
I recommend that GCS implement the new strategy as soon as possible. The potential
benefits of the new strategy outweigh the risks. The cross-functional team should be
established immediately and begin the needs assessment process. The team should then
develop a plan to implement the new strategy.